Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Mexico
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AMGN*:MM

2,290.15 MXN 16.80 0.73%

As of 16:09:22 ET on 01/28/2015.

Snapshot for Amgen Inc (AMGN*)

Open: 2,311.56 Day's Range: 2,290.00 - 2,311.56 Volume: 1,007
Previous Close: 2,306.95 52wk Range: 1,433.85 - 2,486.70 1-Yr Rtn: +45.43%

Stock Chart for AMGN*

No chart data available.
  • AMGN*:MM 2,311.56
  • 1D
  • 1M
  • 1Y
2,306.95
Interactive AMGN* Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AMGN*

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 16.3438
Relative P/E vs. MEXBOL -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 9.3460
Est. PEG Ratio 1.5054
Market Cap (M MXN) 1,742,048.40
Shares Outstanding (M) 760.67
30 Day Average Volume 1,749
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 2.04%
Cash Dividend (USD) 0.7900
Dividend Ex-Date 02/10/2015
5 Year Dividend Growth -
Next Earnings Announcement 04/22/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AMGN*

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AMGN*

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

Robert A Bradway "Bob"Chairman/President/CEODavid W MelineExec VP/CFO
Anthony C Hooper "Tony"Exec VP:Global Commercial OpsBrian M McNameeExec VP:Full Potential Initiatives
More Company Profile & Key Executives for AMGN*

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil